Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-cash Items (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Non-cash Items for 10 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items changed N/A to $11.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $11.1 million for FY2025, N/A changed from the prior year.
  • Non-cash Items for Q4 2025 was $11.1 million at Theravance Biopharma, up from $859000.0 in the prior quarter.
  • The five-year high for Non-cash Items was $11.1 million in Q4 2025, with the low at $775000.0 in Q4 2022.
  • Average Non-cash Items over 4 years is $3.5 million, with a median of $964500.0 recorded in 2021.
  • The sharpest move saw Non-cash Items decreased 27.57% in 2022, then grew 10.84% in 2023.
  • Over 4 years, Non-cash Items stood at $1.1 million in 2021, then fell by 27.57% to $775000.0 in 2022, then rose by 10.84% to $859000.0 in 2023, then skyrocketed by 1197.21% to $11.1 million in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $11.1 million, $859000.0, and $775000.0 for Q4 2025, Q4 2023, and Q4 2022 respectively.